Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST
18 August 2020 - 10:16PM
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH
and OTCQB: ACHFF) will host a webinar today at 11:00am EST to
present an overview of the LSALT Peptide development program and
upcoming Phase II human trial to treat inflammation in patients
with severe complications from Covid-19. The presenters of the
webinar will include key members of the Arch science and management
team, including LSALT co-inventors Dr. Stephen Robbins, Ph.D. Donna
Senger Ph.D., Dr. Daniel Muruve, Chief Science Officer and Dr.
David Luke, author of the Phase II protocol. A live
Q&A session will follow the presentation.
To participate in the webinar, please register here:
https://forms.gle/V4MtwX5dEX3EADWu7
Questions can be submitted in the link above or
anonymously during the event.
About the Phase II trial for LSALT
Peptide
The Phase II trial will be a multicenter,
randomized, double-blind, placebo-controlled, proof of concept
study of LSALT peptide as prevention of organ inflammation known to
trigger acute respiratory distress syndrome (ARDS) and acute kidney
injury (AKI) in patients infected with SARS-CoV-2 (Covid-19).
The composite primary endpoint of the phase II
trial reflects the severe effects often experienced by hospitalized
Covid-19 patients and deemed appropriate for LSALT peptide’s novel
mechanism of action in blocking consequential inflammation in the
lungs and kidneys.
The Phase II results will be used to design a
Phase III registration trial, including higher patient numbers and
optimal drug dosing.
About Arch Biopartners
Arch Biopartners Inc. is a clinical stage
company focused on the development of innovative technologies that
have the potential to make a significant medical or commercial
impact. Arch is developing a pipeline of new drug candidates
that inhibit inflammation in the lungs, liver and kidneys via the
dipeptidase-1 (DPEP-1) pathway for multiple medical
indications.
LSALT peptide (Metablok) is a novel peptide drug
candidate and the lead DPEP-1 inhibitor in the Arch development
pipeline. In August 2019, a scientific team led by Arch scientists
Drs. Senger and Robbins published a paper in the journal Cell
describing a novel mechanism of action for organ inflammation. In
the publication, DPEP-1 was identified for the first time as a
major leukocyte (white blood cell) adhesion receptor on the lung,
liver and kidney endothelium in pre-clinical models. LSALT differs
from typical anti-inflammatory drugs by targeting this novel
adhesion receptor rather than targeting individual cytokines, of
which there are over 30 currently known.
A total of 40 out of 52 healthy, normal
volunteers received LSALT peptide during the recent
placebo-controlled Phase I human trial. In all cases, Metablok was
well tolerated during the trial and no significant drug-related
adverse effects were observed.
For more information on Arch Biopartners, its
technologies and other public documents Arch has filed on SEDAR,
please visit www.archbiopartners.com
The Company has 60,782,302 common shares
outstanding.
Forward-Looking Statements
All statements, other than statements of
historical fact, in this news release are forward looking
statements that involve various risks and uncertainties, including,
without limitation, statements regarding the future plans and
objectives of the Company. There can be no assurance that such
statements will prove to be accurate. Actual results and future
events could differ materially from those anticipated in such
statements. These and all subsequent written and oral
forward-looking statements are based on the estimates and opinions
of management on the dates they are made and are expressly
qualified in their entirety by this notice. The Company assumes no
obligation to update forward-looking statements should
circumstances or management’s estimates or opinions change.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For more information, please contact:
Richard Muruve
Chief Executive Officer
Arch Biopartners, Inc.
647-428-7031
info@archbiopartners.com
Arch Biopartners (TSXV:ARCH)
Historical Stock Chart
From Apr 2024 to May 2024
Arch Biopartners (TSXV:ARCH)
Historical Stock Chart
From May 2023 to May 2024